Table 4 Development of PRO data submissions for rare diseases over time
| Items | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assessment processes | 10 | 16 | 17 | 15 | 13 | 3 | 5 | 2 | ||||||||
| Clinical PROs | 4 | 40% | 12 | 75% | 11 | 65% | 6 | 40% | 4 | 31% | 0 | 0% | 0 | 0% | 0 | 0% |
| HRQoL | 6 | 60% | 13 | 81% | 13 | 76% | 11 | 73% | 10 | 77% | 2 | 67% | 4 | 80% | 2 | 100% |
| Preferences | 1 | 10% | 1 | 6% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| Satisfaction | 0 | 0% | 0 | 0% | 1 | 6% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |